Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study

Bristol-Myers Squibb's HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study results published recently in Lancet HIV. Findings from a subgroup analysis at 48 weeks, presented at IDWeek 2015 this week in San Diego, showed that response rates were similar regardless of demographics or baseline viral load or CD4 cell count.

alt

Read more:

ICAAC 2015: No Transmission of Integrase Inhibitor-Resistant HIV Seen in California Patients

Not one case of transmission of HIV that is resistant to any of the integrase inhibitor drugs has been seen among newly diagnosed patients in a database of resistance tests in California, according to a presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)last month in San Diego.

alt

Read more:

Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, September 17-21, 2015.

Highlights of this year's conference include experimental antiretroviral drugs and treatment strategies, HIV prevention, and comorbidities among people with HIV and HIV/HCV coinfection.

Full listing by topic

ICAAC website

10/6/15

alt

IDWeek 2015: Affordable Care Act Coverage Improves Chances of HIV Viral Suppression

Enrolling low-income and under-insured people with HIV in an Affordable Care Act (ACA) health plan improves their odds of having sustained antiretroviral treatment and undetectable viral load, according to a presentation at ID Week 2015 in San Diego. This study adds to the recent evidence confirming the benefits of providing healthcare coverage for people living with HIV.

alt

Read more:

Coverage of IDWeek 2015

HIVandHepatitis.com coverage of IDWeek 2015, October 7-11 in San Diego.

Conference highlights include new HIV therapies and treatment strategies, HIV and hepatitis C continuums of care, and comorbidities among people with HIV and HIV/HCV coinfection, as well as news about antibiotic stewardship and other infectious diseases including Ebola virus.

Full listing of coverage by topic

IDWeek website

10/9/15

alt

 

IDWeek 2015 Features HIV and Hepatitis C Prevention, Treatment, and Cure Research

Immediate antiretroviral therapy is the big HIV news of the year and interferon-free therapy has transformed the treatment of hepatitis C despite its high cost, experts said during an overview of "What's Hot" in the field, presented at the IDWeek 2015 conference taking place this week in San Diego. Participants also heard a keynote talk by Ian Crozier, a doctor who survived Ebola virus disease.

alt

Read more:

High Standards of Care Associated with Reduced Mortality Risk for Veterans with HIV

Quality of care (QOC) during the first 12 months after entering HIV care is associated with longer-term mortality risk, investigators from the U.S. Department of Veterans Affairs report in the September 3 online edition of Clinical Infectious Diseases. Patients who received at least 80% of recommended quality of care indicators were 25% less likely to die during follow-up when compared to those who received less than 80%. Good outcomes were observed for people with drug or alcohol problems who received a high level of care.

alt

Read more: